Kristen K. Buck's Insider Trades & SAST Disclosures
Kristen K. Buck's most recent trade in Lisata Therapeutics Inc was a trade of 25,000 Common Stock done . Disclosure was reported to the exchange on Jan. 9, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kristen K. Buck.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 25,000 | 87,672 (0%) | 0% | 0 | Common Stock | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 09 Jan 2025 | 2,863 | 82,158 (0%) | 0% | 3.8 | 10,879 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 09 Jan 2025 | 2,651 | 85,021 (0%) | 0% | 3.8 | 10,074 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 09 Jan 2025 | 1,908 | 80,250 (0%) | 0% | 3.8 | 7,250 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.73 per share. | 09 Jan 2025 | 456 | 79,794 (0%) | 0% | 3.7 | 1,701 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 2.93 per share. | 01 Oct 2024 | 15,000 | 69,035 (0%) | 0% | 2.9 | 43,950 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 01 Oct 2024 | 6,363 | 62,672 (0%) | 0% | 2.9 | 18,644 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2024 | 27,000 | 59,915 (0%) | 0% | 0 | Common Stock | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2024 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 09 Jan 2024 | 3,221 | 56,694 (0%) | 0% | 3.1 | 9,921 | Common Stock |
| Lisata Therapeutics Inc | K. Kristen Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 09 Jan 2024 | 2,147 | 54,547 (0%) | 0% | 3.1 | 6,613 | Common Stock |
| Lisata Therapeutics Inc | Kristen Buck K. | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.00 per share. | 09 Jan 2024 | 512 | 54,035 (0%) | 0% | 3 | 1,536 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 18,000 | 38,482 (0%) | 0% | 0 | Common Stock | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 9,000 | 9,000 | - | - | Stock Options (Right to Buy) | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.00 per share. | 09 Jan 2023 | 2,147 | 36,335 (0%) | 0% | 3 | 6,441 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 09 Jan 2023 | 512 | 35,823 (0%) | 0% | 3.2 | 1,636 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.50 per share. | 01 Sep 2022 | 58,000 | 377,203 (3%) | 0% | 0.5 | 29,000 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.50 per share. | 01 Sep 2022 | 44,776 | 307,244 (2%) | 0% | 0.5 | 22,388 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.50 per share. | 01 Sep 2022 | 25,183 | 352,020 (3%) | 0% | 0.5 | 12,592 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 64,500 | 326,897 (3%) | 0% | 0 | Common Stock | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.92 per share. | 10 Jan 2022 | 7,694 | 319,203 (3%) | 0% | 0.9 | 7,055 | Common Stock |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 1,137,915 | 1,137,915 | - | - | Stock Option (Right to Buy) | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 312,500 | 312,500 (2%) | 2% | 0 | Common Stock | |
| Lisata Therapeutics Inc | Kristen K. Buck | EVP, R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.28 per share. | 01 Sep 2021 | 50,103 | 262,397 (2%) | 0% | 1.3 | 64,132 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges